The U.S. Food and Drug Administration (FDA) has approved the first-ever artificial intelligence tool designed to assist doctors in evaluating severe fatty liver disease during clinical drug trials. What AIM-NASH Does Advancing MASH Drug Development Benefits of the AI Tool Human Oversight Retained Source: USFDA
